Parametric Portfolio Associates LLC Buys 9,646 Shares of Enzo Biochem, Inc. (ENZ)
Parametric Portfolio Associates LLC increased its stake in Enzo Biochem, Inc. (NYSE:ENZ) by 26.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,718 shares of the medical research company’s stock after acquiring an additional 9,646 shares during the period. Parametric Portfolio Associates LLC owned approximately 0.10% of Enzo Biochem worth $516,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ENZ. Legal & General Group Plc boosted its position in shares of Enzo Biochem by 10.6% during the second quarter. Legal & General Group Plc now owns 10,663 shares of the medical research company’s stock valued at $119,000 after buying an additional 1,022 shares during the period. OMERS ADMINISTRATION Corp bought a new stake in shares of Enzo Biochem during the second quarter valued at approximately $155,000. KCG Holdings Inc. bought a new stake in shares of Enzo Biochem during the first quarter valued at approximately $141,000. Brookstone Capital Management bought a new stake in shares of Enzo Biochem during the second quarter valued at approximately $221,000. Finally, American International Group Inc. raised its stake in shares of Enzo Biochem by 7.1% during the first quarter. American International Group Inc. now owns 24,432 shares of the medical research company’s stock valued at $204,000 after acquiring an additional 1,610 shares in the last quarter. Institutional investors own 63.99% of the company’s stock.
Several analysts have recently weighed in on ENZ shares. BidaskClub downgraded shares of Enzo Biochem from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Zacks Investment Research downgraded shares of Enzo Biochem from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th. Finally, TheStreet downgraded shares of Enzo Biochem from a “b” rating to a “c+” rating in a research note on Wednesday, September 27th.
Shares of Enzo Biochem, Inc. (ENZ) opened at $9.42 on Friday. Enzo Biochem, Inc. has a 12 month low of $6.27 and a 12 month high of $12.04.
In other news, EVP James Michael O’brien sold 22,866 shares of the company’s stock in a transaction on Friday, October 27th. The stock was sold at an average price of $10.28, for a total transaction of $235,062.48. Following the transaction, the executive vice president now directly owns 34,886 shares of the company’s stock, valued at $358,628.08. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Elazar Rabbani sold 72,401 shares of the company’s stock in a transaction on Wednesday, October 25th. The stock was sold at an average price of $10.09, for a total value of $730,526.09. Following the transaction, the chief executive officer now directly owns 2,038,474 shares in the company, valued at $20,568,202.66. The disclosure for this sale can be found here. Insiders sold 191,398 shares of company stock valued at $1,925,292 in the last three months. 9.50% of the stock is currently owned by insiders.
Enzo Biochem Profile
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.